Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.10
NAS:SYNH's Cash-to-Debt is ranked lower than
93% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. NAS:SYNH: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SYNH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.21 Max: 0.37
Current: 0.1
0.1
0.37
Equity-to-Asset 0.42
NAS:SYNH's Equity-to-Asset is ranked lower than
77% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NAS:SYNH: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SYNH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.23 Max: 0.42
Current: 0.42
0.18
0.42
Debt-to-Equity 1.01
NAS:SYNH's Debt-to-Equity is ranked lower than
82% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. NAS:SYNH: 1.01 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:SYNH' s Debt-to-Equity Range Over the Past 10 Years
Min: 1.01  Med: 1.67 Max: 2.31
Current: 1.01
1.01
2.31
Debt-to-EBITDA 31.07
NAS:SYNH's Debt-to-EBITDA is ranked lower than
98% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.65 vs. NAS:SYNH: 31.07 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:SYNH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.42  Med: 5.24 Max: 31.07
Current: 31.07
2.42
31.07
Piotroski F-Score: 4
Altman Z-Score: 0.79
Beneish M-Score: -1.00
WACC vs ROIC
6.53%
3.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Net Margin % -4.29
NAS:SYNH's Net Margin % is ranked lower than
51% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.33 vs. NAS:SYNH: -4.29 )
Ranked among companies with meaningful Net Margin % only.
NAS:SYNH' s Net Margin % Range Over the Past 10 Years
Min: -9.08  Med: -3.08 Max: 8.37
Current: -4.29
-9.08
8.37
ROE % -10.04
NAS:SYNH's ROE % is ranked lower than
52% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. NAS:SYNH: -10.04 )
Ranked among companies with meaningful ROE % only.
NAS:SYNH' s ROE % Range Over the Past 10 Years
Min: -37.63  Med: -8.14 Max: 43.41
Current: -10.04
-37.63
43.41
ROA % -3.45
NAS:SYNH's ROA % is ranked higher than
52% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.74 vs. NAS:SYNH: -3.45 )
Ranked among companies with meaningful ROA % only.
NAS:SYNH' s ROA % Range Over the Past 10 Years
Min: -9.4  Med: -1.9 Max: 9.54
Current: -3.45
-9.4
9.54
ROC (Joel Greenblatt) % -16.04
NAS:SYNH's ROC (Joel Greenblatt) % is ranked lower than
51% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.40 vs. NAS:SYNH: -16.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SYNH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -154.57  Med: 72.45 Max: 331.19
Current: -16.04
-154.57
331.19
3-Year Revenue Growth Rate 14.80
NAS:SYNH's 3-Year Revenue Growth Rate is ranked higher than
74% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. NAS:SYNH: 14.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SYNH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.8 Max: 14.8
Current: 14.8
0
14.8
3-Year EBITDA Growth Rate 29.40
NAS:SYNH's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.50 vs. NAS:SYNH: 29.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SYNH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 29.4 Max: 56.1
Current: 29.4
0
56.1
GuruFocus has detected 1 Warning Sign with Syneos Health Inc NAS:SYNH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SYNH's 30-Y Financials

Financials (Next Earnings Date: 2018-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

SYNH Guru Trades in Q1 2017

Jeremy Grantham 5,000 sh (New)
George Soros 84,700 sh (New)
Steven Cohen 493,118 sh (+19624.72%)
Joel Greenblatt 15,274 sh (-7.58%)
Jim Simons 177,400 sh (-36.14%)
Ron Baron 750,000 sh (-42.31%)
Pioneer Investments 47,787 sh (-67.24%)
Paul Tudor Jones 20,592 sh (-92.48%)
» More
Q2 2017

SYNH Guru Trades in Q2 2017

Caxton Associates 5,100 sh (New)
Jim Simons 621,300 sh (+250.23%)
Jeremy Grantham 5,000 sh (unchged)
Pioneer Investments Sold Out
George Soros Sold Out
Paul Tudor Jones 16,781 sh (-18.51%)
Ron Baron 500,000 sh (-33.33%)
Joel Greenblatt 9,907 sh (-35.14%)
Steven Cohen 41,600 sh (-91.56%)
» More
Q3 2017

SYNH Guru Trades in Q3 2017

Steven Cohen 598,039 sh (+1337.59%)
Joel Greenblatt 14,834 sh (+49.73%)
Ron Baron 500,000 sh (unchged)
Caxton Associates 5,100 sh (unchged)
Jeremy Grantham Sold Out
Jim Simons 611,629 sh (-1.56%)
Paul Tudor Jones 15,800 sh (-5.85%)
» More
Q4 2017

SYNH Guru Trades in Q4 2017

Jana Partners 1,321,586 sh (New)
Andreas Halvorsen 1,558,512 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ron Baron Sold Out
Caxton Associates Sold Out
Steven Cohen 241,400 sh (-59.63%)
» More
» Details

Insider Trades

Latest Guru Trades with SYNH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Add 49.73%$51.65 - $59.05 $ 38.40-31%14,834
Ron Baron 2017-06-30 Reduce -33.33%0.06%$40.9 - $60.65 $ 38.40-26%500,000
Joel Greenblatt 2017-06-30 Reduce -35.14%$40.9 - $60.65 $ 38.40-26%9,907
George Soros 2017-06-30 Sold Out 0.11%$40.9 - $60.65 $ 38.40-26%0
Ron Baron 2017-03-31 Reduce -42.31%0.17%$43.45 - $56.55 $ 38.40-23%750,000
George Soros 2017-03-31 New Buy0.11%$43.45 - $56.55 $ 38.40-23%84,700
Joel Greenblatt 2017-03-31 Reduce -7.58%$43.45 - $56.55 $ 38.40-23%15,274
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711    SIC: 8731
Compare:MIL:DIA, NAS:VWR, NAS:DXCM, NYSE:CRL, NAS:BRKR, XTER:AFX, SHSE:603658, NAS:PRAH, NAS:ICLR, XTER:SRT3, BSP:FLRY3, NAS:EXAS, BSP:DASA3, NAS:FMI, TSE:4544, NAS:NEOG, NAS:MYGN, SHSE:603882, NAS:QGEN, SZSE:300463 » details
Traded in other countries:8IN.Germany,
Headquarter Location:USA
Syneos Health Inc is a Contract Research Organization providing clinical development services for biopharmaceutical & medical device industries. It operates in North America, Europe, Middle East and Africa, Asia-Pacific and Latin America.

Syneos Health Inc, formerly known as INC Research/inVentiv Health is a global contract research and commercialization organization that provides services to pharmaceutical and biotechnology companies. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Ratios

vs
industry
vs
history
Forward PE Ratio 11.27
SYNH's Forward PE Ratio is ranked higher than
97% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.31 vs. SYNH: 11.27 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.34
SYNH's PB Ratio is ranked higher than
91% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. SYNH: 1.34 )
Ranked among companies with meaningful PB Ratio only.
SYNH' s PB Ratio Range Over the Past 10 Years
Min: 1.26  Med: 8.35 Max: 12.19
Current: 1.34
1.26
12.19
PS Ratio 1.25
SYNH's PS Ratio is ranked higher than
84% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.54 vs. SYNH: 1.25 )
Ranked among companies with meaningful PS Ratio only.
SYNH' s PS Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.71 Max: 2.41
Current: 1.25
1.08
2.41
Price-to-Free-Cash-Flow 25.97
SYNH's Price-to-Free-Cash-Flow is ranked higher than
55% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.50 vs. SYNH: 25.97 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SYNH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.74  Med: 19.26 Max: 39.95
Current: 25.97
11.74
39.95
Price-to-Operating-Cash-Flow 17.68
SYNH's Price-to-Operating-Cash-Flow is ranked higher than
63% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.22 vs. SYNH: 17.68 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SYNH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.49  Med: 16.52 Max: 28.04
Current: 17.68
9.49
28.04
EV-to-EBITDA 68.70
SYNH's EV-to-EBITDA is ranked lower than
96% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.87 vs. SYNH: 68.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
SYNH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.2  Med: 19.2 Max: 80.3
Current: 68.7
12.2
80.3
EV-to-Revenue 3.41
SYNH's EV-to-Revenue is ranked higher than
57% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.12 vs. SYNH: 3.41 )
Ranked among companies with meaningful EV-to-Revenue only.
SYNH' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 2 Max: 3.9
Current: 3.41
1.4
3.9
Current Ratio 1.27
SYNH's Current Ratio is ranked lower than
82% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. SYNH: 1.27 )
Ranked among companies with meaningful Current Ratio only.
SYNH' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 1.14 Max: 1.27
Current: 1.27
0.89
1.27
Quick Ratio 1.27
SYNH's Quick Ratio is ranked lower than
72% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. SYNH: 1.27 )
Ranked among companies with meaningful Quick Ratio only.
SYNH' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 1.14 Max: 1.27
Current: 1.27
0.89
1.27
Days Sales Outstanding 175.14
SYNH's Days Sales Outstanding is ranked lower than
91% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.41 vs. SYNH: 175.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
SYNH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 76.9  Med: 83.94 Max: 175.14
Current: 175.14
76.9
175.14
Days Payable 15.92
SYNH's Days Payable is ranked lower than
92% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.40 vs. SYNH: 15.92 )
Ranked among companies with meaningful Days Payable only.
SYNH' s Days Payable Range Over the Past 10 Years
Min: 4.52  Med: 7.17 Max: 15.92
Current: 15.92
4.52
15.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.10
SYNH's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -8.00 vs. SYNH: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SYNH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.1  Med: -1.1 Max: 0
Current: -1.1
-1.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.73
SYNH's Price-to-Median-PS-Value is ranked higher than
70% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.95 vs. SYNH: 0.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SYNH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.69  Med: 0.97 Max: 1.21
Current: 0.73
0.69
1.21
Earnings Yield (Greenblatt) % -0.21
SYNH's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.04 vs. SYNH: -0.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SYNH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -0.21  Med: 3.4 Max: 5.9
Current: -0.21
-0.21
5.9

More Statistics

Revenue (TTM) (Mil) $2,001.45
EPS (TTM) $ -0.58
Beta0.71
Short Percentage of Float11.37%
52-Week Range $33.60 - 61.10
Shares Outstanding (Mil)104.34

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 1,869 3,216
EBIT (Mil $) -25 279
EBITDA (Mil $) 160 555
EPS ($) 2.46 3.41
EPS without NRI ($) 2.46 3.41
EPS Growth Rate
(Future 3Y To 5Y Estimate)
17.20%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}